The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells
Abstract
Effective immunotherapy of stromal-rich tumors requires simultaneous targeting of cancer cells and immunosuppressive elements of the microenvironment. Here, we modified the oncolytic group B adenovirus enadenotucirev to express a stroma-targeted bispecific T-cell engager (BiTE). This BiTE bound fibroblast activation protein on cancer-associated fibroblasts (CAF) and CD3ϵ on T cells, leading to potent T-cell activation and fibroblast death. Treatment of fresh clinical biopsies, including malignant ascites and solid prostate cancer tissue, with FAP-BiTE–encoding virus induced activation of tumor-infiltrating PD1+ T cells to kill CAFs. In ascites, this led to depletion of CAF-associated immunosuppressive factors, upregulation of proinflammatory cytokines, and increased gene expression of markers of antigen presentation, T-cell function, and trafficking. M2-like ascites macrophages exhibited a proinflammatory repolarization, indicating spectrum-wide alteration of the tumor microenvironment. With this approach, we have actively killed both cancer cells and tumor fibroblasts, reversing CAF-mediated immunosuppression and yielding a potent single-agent therapeutic that is ready for clinical assessment. Significance: An engineered oncolytic adenovirus that encodes a bispecific antibody combines direct virolysis with endogenous T-cell activation to attack stromal fibroblasts, providing a multimodal treatment strategy within a single therapeutic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · cited 1×
“Notably secreted TGFb can accumulate in the stromal matrix, exerting a powerful immunosuppressive effect on newly infiltrating na€ ve immune cells (9, 10), while CAF-produced CXCL12 can block entry of CD8þ cells into the tumor and attract regulatory T cells, inhibiting effector T-cell proliferation (11, 12).”
BackgroundThe polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
VEGF-A and Tenascin-C produced by S100A4 + stromal cells are important for metastatic colonization
O'Connell, J. T., Sugimoto, H., Cooke, V. G., MacDonald, B. A., Mehta, A. I., LeBleu, V. S., Dewar, R., Rocha, R. M., Brentani, R. R., Resnick, M. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109493108 · Cited by 348
Fearon, D. T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0002 · Cited by 288
Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression
Tang, D., Gao, J., Wang, S., Ye, N., Chong, Y., Huang, Y., Wang, J., Li, B., Yin, W., & Wang, D. (2016) · Tumor Biology · doi:10.1007/s13277-015-3942-9 · Cited by 138
Cited by
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0770-1 · Cited by 860
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Biomarkers for cancer-associated fibroblasts
Han, C., Liu, T., & Yin, R. (2020) · Biomarker Research · doi:10.1186/s40364-020-00245-w · Cited by 299
Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities
Hu, D., Li, Z., Zheng, B., Lin, X., Pan, Y., Gong, P., Zhuo, W., Hu, Y., Chen, C., Chen, L., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12291 · Cited by 286
Cancer-associated fibroblasts: overview, progress, challenges, and directions
Ping, Q., Yan, R., Cheng, X., Wang, W., Zhong, Y., Hou, Z., Shi, Y., Wang, C., & Li, R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00318-4 · Cited by 285
Metadata
- Authors
- Freedman, J. D., Duffy, M. R., Lei-Rossmann, J., Muntzer, A., Scott, E. M., Hagel, J., Campo, L., Bryant, R. J., Verrill, C., Lambert, A., Miller, P., Champion, B. R., Seymour, L. W., & Fisher, K. D.
- Venue
- Cancer Research
- Published
- 2018-12-13
- Volume
- 78
- Issue
- 24
- Pages
- 6852-6865
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2901123261
- Cited by
- 170
- References
- 6
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-1750
- The paper
- Freedman, J. D., Duffy, M. R., Lei-Rossmann, J., Muntzer, A., Scott, E. M., Hagel, J., Campo, L., Bryant, R. J., Verrill, C., Lambert, A., Miller, P., Champion, B. R., Seymour, L. W., & Fisher, K. D. (2018). An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-1750
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.